 |
|
|
| |
LIK066 (licogliflozin), an SGLT1/2 inhibitor, robustly decreases ALT and improves markers of hepatic and metabolic health in patients with nonalcoholic fatty liver disease: Interim analysis of a 12-week, randomized, placebo-controlled, Phase 2a study
|
| |
| |
Stephen A. Harrison1, Frederico Perez Manghi2, William B. Smith3, Diana Alpenidze4, Diego Aizenberg5,
Koos Burggraaf6, Chi-Ye Chen7, Eli Zuckerman8, Eric Ravussin9, Phunchai Charatcharoenwitthaya10, Pin-Nan Cheng11, Helena Katchman12, Samuel Klein13, Ziv Ben-Ari14, Anisha Mendonza15, Yiming Zhang16, Miljen Martic17,
Shenglin Ma15, Sheena Kao18, Sandra Tanner17, Alok Pachori15, YanLing He15, Chinweike Ukomadu15 and Eric Sicard19
1Pinnacle Clinical Research, San Antonio, USA; 2CINME, Buenos Aires, Argentina; 3New Orleans Center for Clinical Research, Knoxville, USA; 4City Out-patient Clinic #117, St. Petersburg, Russia; 5Centro Medico Viamonte, Buenos Aires, Argentina; 6Center for Human Drug Research, Leiden, Netherlands; 7Chiayi Christian Hospital, Taiwan; 8Carmel Medical Center, Haifa, Israel; 9Pennington Biomedical Research Center; Baton Rouge, USA; 10Siriraj Hospital, Bangkok, Thailand; 11National Cheng Kung University Hospital, Taiwan;12Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; 13Washington University School of Medicine, St. Louis, USA; 14Sheba Medical Center, Ramat Gan, Israel; 15Novartis Institutes For BioMedical Research, Cambridge, USA; 16Novartis Institutes For BioMedical Research, East Hanover, USA; 17Novartis Institutes For BioMedical Research, Basel, Switzerland; 18Novartis Institutes For Biomedical Research, Shanghai, China;19Altasciences Algorithme Pharma, Quebec, Canada
|
| |
|
|
|
|
|
